U.S. Markets closed
LISTEN

Schultz: Businesses need to do more to help people

Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz

InVivo Therapeutics Holdings Corp. (NVIV)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
1.40+0.05 (+3.70%)
At close: 4:00PM EDT

1.40 +0.05 (3.70%)
After hours: 4:00PM EDT

People also watch
AVXLCURONCSADXSBCLI
Full screen
Previous Close1.35
Open1.35
Bid1.15 x 200
Ask1.45 x 500
Day's Range1.32 - 1.40
52 Week Range1.10 - 6.97
Volume154,352
Avg. Volume401,101
Market Cap47.89M
Beta3.20
PE Ratio (TTM)-1.83
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals24 days ago

    InVivo slashes staff and ousts science chief

    Cambridge-based InVivo Therapeutics said on Monday said that it plans to lay off more than a third of its workforce and terminate its chief scientific officer. The latest news comes one month after the company reported that a third patient had died in a trial of its experimental spinal cord injury treatment. In a separate federal filing, the company said it had notified its chief scientific officer, Thomas Ulich, that he will be terminated effective on Wednesday.

  • Associated Presslast month

    InVivo reports 2Q loss

    The Cambridge, Massachusetts-based company said it had a loss of 20 cents per share. The company's shares closed at $1.80. A year ago, they were trading at $6.36. _____ This story was generated by Automated ...

  • American City Business Journals2 months ago

    InVivo halts trial of spine injury treatment after third patient dies

    InVivo Therapeutics said Monday it has halted a trial of its spinal cord injury treatment after a third patient died, sending shares of the Cambridge company plummeting. InVivo (NVIV) announced that it would temporarily stop enrolling patients in the trial of its Neuro-Spinal Scaffold, a biodegradable device invented in part by MIT professor Bob Langer designed to help patients heal after spinal cord injuries.